EP0723536B1 - Ein aglucon isoflavon angereichertes pflanzliches molkeprotein, das molkeprotein und ein verfahren zur herstellung - Google Patents

Ein aglucon isoflavon angereichertes pflanzliches molkeprotein, das molkeprotein und ein verfahren zur herstellung Download PDF

Info

Publication number
EP0723536B1
EP0723536B1 EP94928641A EP94928641A EP0723536B1 EP 0723536 B1 EP0723536 B1 EP 0723536B1 EP 94928641 A EP94928641 A EP 94928641A EP 94928641 A EP94928641 A EP 94928641A EP 0723536 B1 EP0723536 B1 EP 0723536B1
Authority
EP
European Patent Office
Prior art keywords
whey
process according
protein
isoflavones
aglucone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP94928641A
Other languages
English (en)
French (fr)
Other versions
EP0723536B2 (de
EP0723536A1 (de
EP0723536A4 (de
Inventor
Jerome L. Shen
Barbara A. Bryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archer Daniels Midland Co
Original Assignee
Protein Technologies International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22466955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0723536(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protein Technologies International Inc filed Critical Protein Technologies International Inc
Publication of EP0723536A1 publication Critical patent/EP0723536A1/de
Publication of EP0723536A4 publication Critical patent/EP0723536A4/de
Application granted granted Critical
Publication of EP0723536B1 publication Critical patent/EP0723536B1/de
Publication of EP0723536B2 publication Critical patent/EP0723536B2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones

Definitions

  • the present invention relates to the production of an aglucone isoflavone enriched vegetable protein whey and whey protein, by reacting a vegetable protein whey containing protein and isoflavones with one or more beta-glucosidase enzymes or acid to convert substantially all the glucone isoflavones to aglucones and thereby provide the aglucone enriched whey.
  • An aglucone enriched whey protein is also obtained by recovery of the protein from the enriched whey.
  • Isoflavones occur in a variety of leguminous plants, including vegetable protein materials such as soybeans. These compounds include daidzin, 6-OAc daidzin, 6"-OMal daidzin, daidzein, genistin, 6"-OAc genistin, 6"-OMal genistin, genistein, glycitin, 6"-OAc-glycitin, 6"-OMal-glycitin, glycitein, biochanin A, formononetin and coumestrol. Typically these compounds are associated with the inherent, bitter flavor of soybeans, and in the production of commercial products, such as isolates and concentrates, the focus has been to remove these materials.
  • isoflavones several exist as glucosides, or as glucones, with a glucose molecule attached at the seven position as illustrated in the formula below.
  • glucones such as the 6"-OAc genistin, contain an acetate group attached to the six position of the glucose molecule itself. While all the isoflavones, including the glucosides are of interest in medical evaluation, the specific isoflavones of most interest are the aglucones, wherein the glucose molecule is not attached. These isoflavones are not as water soluble as the glucones or glucosides.
  • isoflavones in this category are daidzein, genistein, and glycitein. These aglucones have the following general formula: wherein. R 1 , R 2 , R 3 and R 4 may be selected from the group consisting of H, OH and OCH 3 . It is therefore to the aglucones and enrichment of a vegetable protein whey or whey protein with these materials to which the present invention is directed.
  • US-A-4,064,277 discloses that residual ⁇ -glucosidase enzyme contained in whole soy beans reacts with glycoside substrates to form, for example, daidzein and glycitein. This reference teaches that processing of soy beans, before the ⁇ -glucosidase is inactivated, should be effected in the presence of a competitive inhibitor for ⁇ -glucosidase, in order to provide a soy bean product that does not produce a throat-catching sensation.
  • US-A-4,889,921 discloses a method of preparing a vegetable protein isolate, particularly from rapeseed or canola material, by extracting with an aqueous solvent to form an extraction solution, adjusting the pH to precipitate proteins from the solution, and separating the precipitated protein by ultra- or diafiltration to form a vegetable protein isolate.
  • Coward et al. 'Genistein, Daidzein and their ⁇ -Glycoside Conjugates: Antitumor Isoflavones in Soybean Foods from American and Asian Diets', Journal of Agricultural Food Chemistry, Vol. 41, No. 11, 1993, p1961-1967 discloses that soy protein isolate, prepared by solubilization of proteins and soluble carbohydrates from soy flour by an alkaline (pH 9.5) extraction step and subsequent acid (pH 4.5) precipitation of the extracted protein, contains isoflavone concentrations that are 4-6 times lower than in soy flour or soy protein concentrate, when expressed as milligrams per gram of protein.
  • soy protein isolate prepared by solubilization of proteins and soluble carbohydrates from soy flour by an alkaline (pH 9.5) extraction step and subsequent acid (pH 4.5) precipitation of the extracted protein, contains isoflavone concentrations that are 4-6 times lower than in soy flour or soy protein concentrate, when expressed as milligrams
  • the present invention provides processes for producing an aglucone isoflavone enriched vegetable protein whey comprising obtaining a vegetable protein whey comprising glucone isoflavones and reacting the glucone isoflavones with a sufficient amount of at least one of beta-glucosidase and esterase for a time period, temperature, and pH sufficient to convert a majority of the glucone isoflavones in the whey to aglucone isoflavones, and thereby produce an aglucone isoflavone enriched whey.
  • the present invention also provides methods for producing such whey wherein supplemental beta-glucosidase and/or esterase is added to the whey to produce aglucone isoflavone enriched whey.
  • the present invention also provides methods for producing such whey by treatment with one or more acids.
  • the present invention provides aglucone isoflavone enriched vegetable protein whey and whey products.
  • the present invention also provides methods of recovering, in relatively high proportions, isoflavones in whey and whey protein, from vegetable protein materials.
  • soybean whey Although the present invention will be described with respect to soybean whey and although the process is particularly suited for the production of aglucone isoflavone enriched whey from soybean materials, nevertheless the process is generally applicable to the production of aglucone enriched wheys from a variety of vegetable protein sources which contain isoflavones.
  • An example of such a source is a vegetable protein material comprising soy or soybean materials.
  • the term "soybean material" as used herein refers to soybeans or any soybean derivative.
  • the starting material in accordance with the preferred embodiment is soybean flakes, from which the oil has been removed by solvent extraction.
  • the flakes are extracted with an aqueous extractant having a pH above about the isoelectric point of the protein material, preferably a pH of about 6.0 to about 10.0 and most preferably a pH of about 6.7 to about 9.7.
  • Typical alkaline reagents may be employed, if destred to elevate the pH of the aqueous extractant including sodium hydroxide, potassium hydroxide, and calcium hydroxide.
  • the desired isoflavone compounds are typically solubilized in the aqueous extract. It is also desirable, in order to maximize recovery of these compounds in the aqueous extract that the weight ratio of extract to soybean flakes is controlled to specific levels in order to solubilize as much of the inherent isoflavones in the protein material as possible.
  • Extraction of the proteins and isoflavones can be carried out in a variety of ways including countercurrent extraction of the flakes at a weight ratio of aqueous extractant to flakes of about 8:1 to 16:1, in which the initial extract is used to extract the flakes and provide an aqueous extract of protein and isoflavones.
  • a two-step extraction process can be used in which the weight ratio of extractant to flakes in the initial step comprises about 10:1 and then a second extraction of the flakes with fresh extractant takes place at a weight ratio of extractant to flakes of about 6:1, so that the combined weight ratio of extractant to flakes in both steps does not exceed a total weight ratio of extractant to flakes of about 16:1.
  • the pH of the resulting protein extract with solubilized isoflavones is then adjusted to about the isoelectric point of the protein in order to precipitate the protein.
  • the pH is adjusted to about the isoelectric point of the protein by the addition of an edible acid such as acetic, sulfuric, phosphoric, hydrochloric or any other suitable reagent.
  • the isoelectric point for soy protein is typically about 4.4 to 4.6.
  • the protein material is precipitated in the form of a curd which can be separated from the aqueous extract.
  • the remaining aqueous extract of the starting material is referred to as the "whey" of whatever vegetable protein source that is used as the starting material.
  • the isoflavones for the most part remain solubilized in the whey and to maximize recovery in the whey, additional washing of the precipitated protein may be desirable to assure complete recovery of the isoflavones.
  • Glucone isoflavones in the whey are converted to aglucone isoflavones by reaction with enzyme, or reaction with acid. Conversion utilizing an enzyme is as follows. Glucone isoflavones in whey are reacted in a reaction process, with a sufficient amount of one or more beta-glucosidase enzymes to convert a majority, and preferably substantially all isoflavones in glucone form to aglucones.
  • the beta-glucosidase enzyme may be naturally present in the soybean material or present from microbial growth, referred to herein as "residual" enzyme, or may be added to the whey. Added enzyme is referred to herein as "supplemental enzyme".
  • supplemental enzyme should be added.
  • the amount of enzyme sufficient to perform the conversion of isoflavones varies upon a multitude of factors including the types of enzymes present, distribution of enzyme concentrations, pH of the system, and activities of enzymes present.
  • the whey with solubilized isoflavones is reacted with the beta-glucosidase enzymes for a time period, temperature, and pH sufficient to convert a majority and preferably substantially all the glucone isoflavones contained in the whey to the aglucone form.
  • Preferred supplemental beta-glucosidase enzymes include Biopectinase 100L and 300L, Biopectinase OK 70L, Lactase F, and Lactozyme.
  • Lactase F is available from Amano International Enzyme Co, Inc., P.O. Box 1000 Troy, VA 22974, which has an optimum pH range of about 4 to about 6 and Lactozyme is available from Novo Industries, Enzyme Division, Novo Alle, DK 2880 Bagsvaerd, Denmark which has an optimum pH range of about 7.
  • Biopectinase 100L, Biopectinase 300L, and Biopectinase OK 70L are available from Quest International, Sarasota, Florida.
  • Supplemental enzymes are added in amounts sufficient to convert a majority and preferably substantially all the solubilized glucone isoflavones contained in the whey to aglucones. In instances where it is necessary to add supplemental enzymes, the amount of enzyme added is about 0.5% to about 5% by weight of the whey solids on a dry basis.
  • esterase enzymes Another class of enzymes suitable for administration as supplemental enzymes are esterase enzymes. These enzymes are believed to be well suited to the preferred embodiment processes described herein as they convert the acetate and malonate conjugates to glucone isoflavones by removing the acetate and malonate groups from the isoflavone conjugates. In the most preferred embodiment, both types of enzymes, beta-glucosidase and esterase enzymes are utilized.
  • the processes of the preferred embodiment are preferably one-step processes and achieve very high degrees of conversion of isoflavones (from glucone form to aglucone form), in relatively short periods of time, and with relative ease and economy.
  • the term "one-step" reaction process as used herein refers to a reaction process in which certain process parameter values are generally maintained over the course of the reaction process. These process parameters include pH and temperature.
  • the very high degrees of conversion are such that a majority, and preferably, substantially all the isoflavones in glucone form present in the whey are converted to aglucone form.
  • the term "a majority” refers to extent of conversion of glucone isoflavones to aglucone isoflavones of at least about 50 %.
  • the term “substantially all” refers to extent of conversion of glucone isoflavones to aglucone isoflavones of at least about 80%, and most preferably at least about 90%.
  • pH of the reaction system be maintained, or approximately so, at a value of from about 4 to about 8, and most preferably at a value at which the enzyme(s) are most active prior to reaction with the isoflavone conjugate(s) during the one-step reaction process.
  • the pH of the whey is typically adjusted to about the pH range at which the specific enzyme is most active prior to reaction with the enzyme.
  • the temperature of the reaction system be maintained, or approximately so, at a temperature of from about 40° C to about 60° C, and most preferably at a temperature of about 60° C during the one-step reaction process.
  • the time periods necessary to achieve conversion of substantially all glucone isoflavones to aglucones via the one-step processes described herein are from about 2 hours to about 24 hours. In some instances it may be desirable to utilize time periods greater than 24 hours, such as 48 hours.
  • An alternative procedure for purposes of the present invention for conversion of glucone isoflavones to aglucone isoflavones is to react the whey with one or more edible acids at a pH, time, and temperature sufficient to convert a majority and preferably substantially all the glucone isoflavones to aglucone isoflavones. This also tends to insolubilize the protein, thereby enabling the protein to be separated from the remaining whey.
  • a preferred pH range for this procedure is from about 1.0 to about 2.0, typical temperatures are from about 80° C to about 90° C or higher, and typical time periods are from about 30 to about 180 minutes or longer.
  • glucone isoflavones to aglucone isoflavones can also occur at a higher pH. Effective reactions can occur at pH's as high as about pH 4.5. But the reaction is much slower and requires much longer times. For instance, at a pH of 4.5 and temperature of 50° C, a time period of about 24 hours is necessary.
  • the liquid whey may be employed as desired without drying or removal of the protein, or alternatively, the whey protein can be recovered to concentrate the aglucon isoflavones in the protein, since the aglucone isoflavones are less soluble than the glucone isoflavones.
  • Recovery of whey protein enriched with aglucone isoflavones can be accomplished by conventional procedures including dewatering, heat coagulation, and ultrafiltration.
  • the resulting enriched whey protein can be dewatered and dried by conventional means to provide a dried whey protein enriched with aglucone isoflavones.
  • An example of an aglucone isoflavone enriched vegetable whey protein in accordance with the preferred embodiment has a dry basis genistein content of about 2.6 to about 8.7 mg/gram and a dry basis daidzein content of about 2.5 to about 6.0 mg/gram.
  • the present invention also provides methods of recovering isoflavones in whey and whey protein, in very high proportions, from a vegetable protein material such as a soybean material.
  • the recovery levels obtainable by the processes described herein are typically at least 50%, preferably 65%, and most preferably 80%, based upon the total of all forms of the particular isoflavone in the starting vegetable protein material.
  • the beneficial effect of the addition of supplemental enzyme is demonstrated by the significantly higher concentrations of genistein and daidzein, e.g. 70% and 66%, respectively.
  • concentration of each type of isoflavone described herein is based upon the total of all forms of that isoflavone type.
  • Table 2B indicates the isoflavone distribution in samples that had originally been incubated 24 hours without having any supplemental enzyme added, which then received a sufficient amount of Biopectinase 100L.
  • Table 2A illustrate samples having marginally sufficient residual enzyme concentrations since the genistein, daidzein, and glycitein concentrations, after incubation for 24 and 46 hours are less than 50%.
  • Table 2B illustrate the benefits of adding supplemental enzyme, since after addition of the enzyme, conversion was 100% for genistein and daidzein and 87% for glycitein.
  • the percent recovery of genistein and daidzein in a whey protein derived from soybeans was investigated. The percent recovery was found by determining the amount of genistein (or daidzein) in the whey protein, and expressing that amount as a percentage based upon the total amount of all forms of genistein (or daidzein) in the soybean starting material.
  • 100 g of defatted soy flour was extracted with 1000 g of water at 32° C for 15 minutes.
  • the pH of the slurry was 6.7. This provided a ratio of extractant to flour of 10.1.
  • the slurry was then centrifuged for 5 minutes to remove the spent flour.
  • the spent flour was extracted a second time with 600 grams of water at 32° C for 5 minutes. This provided a ratio of extractant to flour of 6:1.
  • the second extract was also separated from the spent flour by centrifugation for 5 minutes.
  • the first and second aqueous extracts were combined.
  • the combined extracts were adjusted to a pH of 4.5 by the addition of HCl to precipitate the protein from the soy whey.
  • the soy whey was spray dried and then resuspended in water to a 20% solids level.
  • the pH of the whey slurry was adjusted to 4.5 and the temperature maintained at 50° C.
  • the isoflavone content was quantified as follows.
  • the isoflavones are extracted from soy products by mixing 0.75 g of sample (spray dried or finely ground powder) with 50 ml of 80/20 methanol/water solvent. The mixture is shaken for 2 hours at room temperature with an orbital shaker. After 2 hours, the remaining undissolved materials are removed by filtration though Whatman No. 42 filter paper. Five ml of the filtrate are diluted with 4 ml of water and 1 ml of methanol.
  • the extracted isoflavones are separated by HPLC (High Performance Liquid Chromatography) using a Beckman C18 reverse phase column.
  • HPLC High Performance Liquid Chromatography
  • the isoflavones are injected on to the column and eluted with a solvent gradient starting with 88% methanol, 10% water, and 2% glacial acetic and ending with 98% methanol and 2% glacial acetic.
  • Quantification is achieved by using pure standards (genistin, genistein, daidzin and daidzein) purchased from Indofine Chemical Company, Sommerville, NJ. Response factors (Integrated area/concentration) are calculated for each of the above compounds and are used to quantitate unknown samples. For the conjugated forms for which no pure standards are available, response factors are assumed to be that of the parent molecule but corrected for molecular weight difference. The response factor for glycitin is assumed to be that for genistin corrected for molecular weight difference.
  • This method provides the quantitites of each individual isoflavone. For convenience, total genistein, total daidzein and total glycitein can be calculated and represent the aggregate weight of these compounds if all the conjugated forms are converted to their respective unconjugated forms. These totals can also be measured directly by a method using acid hydrolysis to convert the conjugated forms.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Claims (34)

  1. Verfahren zum Herstellen einer Aglucon Isoflavon angereicherten Pflanzenproteinmolke, umfassend:
    (a) Erhalten einer Pflanzenproteinmolke, umfassend Glucon Isoflavone, und
    (b) Umsetzen der Glucon Isoflavone mit einer ausreichenden Menge mindestens eines von beta-Glucosidase und Esterase für eine Zeitdauer, Temperatur und pH, ausreichend, mindestens eine Mehrheit der Glucon Isoflavone in der Molke zu Aglucon Isoflavonen umzuwandeln, wodurch eine Aglucon Isoflavon angereicherte Molke hergestellt wird.
  2. Verfahren nach Anspruch 1, wobei die Zeitdauer von 2 Stunden bis 48 Stunden beträgt.
  3. Verfahren nach Anspruch 2, wobei die Zeitdauer 24 Stunden beträgt.
  4. Verfahren nach einem vorhergehenden Anspruch, wobei die Temperatur 40°C bis 60°C beträgt.
  5. Verfahren nach Anspruch 4, wobei die Temperatur 60°C beträgt.
  6. Verfahren nach einem vorhergehenden Anspruch, wobei der pH von 4 bis 8 beträgt.
  7. Verfahren nach Anspruch 6, wobei der pH 4,5 beträgt.
  8. Verfahren nach einem vorhergehenden Anspruch, ferner umfassend:
    (c) Gewinnen eines Proteinmaterials aus der Molke unter zur Verfügung stellen eines Aglucon Isoflavon angereicherten Molkeproteins.
  9. Verfahren nach Anspruch 8, wobei das Molkeprotein Sojabohnenmolke umfaßt.
  10. Verfahren nach Anspruch 8, wobei das Molkeprotein durch Ultrafiltration und/oder Hitzekoagulation und/oder Entwässern gewonnen wird.
  11. Verfahren nach Anspruch 8, wobei das Molkeprotein durch ein Verfahren gewonnen wird, das umfaßt Erhitzen der Molke bei einem pH, Zeit und Temperatur, ausreichend, das Protein unlöslich zu machen, danach Abtrennen des unlöslich gemachten Proteins von der Molke.
  12. Verfahren nach Anspruch 11, wobei der pH 1 bis 2 beträgt.
  13. Verfahren nach Anspruch 11 oder 12, wobei die Temperatur mindestens 80°C für 30 Minuten ist.
  14. Verfahren nach einem von Ansprüchen 11 bis 13, wobei das unlöslich gemachte Protein von der Molke durch Zentrifugation abgetrennt wird.
  15. Verfahren nach einem von Ansprüchen 11 bis 14, wobei das unlöslich gemachte Protein entwässert wird.
  16. Verfahren nach einem vorhergehenden Anspruch, wobei mindestens 80% der Glucon Isoflavone zu Aglucon Isoflavonen umgewandelt werden.
  17. Verfahren nach einem vorhergehenden Anspruch, wobei das Enzym residuales Enzym ist.
  18. Verfahren nach einem von Ansprüchen 1 bis 12, wobei das Enzym ergänzendes Enzym ist.
  19. Verfahren nach einem von Ansprüchen 1 bis 12, wobei das Enzym aus sowohl ergänzendem wie residualem Enzym besteht.
  20. Verfahren nach Anspruch 17, 18 oder 19, wobei das Molkeprotein durch Ultrafiltration gewonnen wird.
  21. Verfahren zum Herstellen einer Aglucon Isoflavon angereicherten Pflanzenproteinmolke, umfassend:
    (a) Erhalten einer Pflanzenproteinmolke, umfassend Glucon Isoflavone, und
    (b) Umsetzen der Glucon Isoflavone mit einer ausreichenden Menge von Säure bei einem pH, Zeit und Temperatur, ausreichend, eine Mehrheit der Glucon Isoflavone in der Molke zu Aglucon Isoflavonen umzuwandeln und dadurch eine Aglucon Isoflavon angereicherte Molke herzustellen.
  22. Verfahren nach Anspruch 21, wobei der pH von 1 bis 2 beträgt.
  23. Verfahren nach Anspruch 22, wobei die Temperatur von 80°C bis 90°C beträgt.
  24. Verfahren nach Anspruch 21, 22 oder 23, wobei die Zeit von 30 Minuten bis 180 Minuten beträgt.
  25. Verfahren nach Anspruch 21, wobei der pH 4,5 beträgt.
  26. Verfahren nach Anspruch 25, wobei die Temperatur 50°C beträgt, insbesondere wobei die Zeit 24 Stunden beträgt.
  27. Verfahren nach einem von Ansprüchen 1 bis 20, wobei der pH bei einem Wert ist, bei dem das Enzym äußerst aktiv vor Reaktion mit den Glucon Isoflavonen ist.
  28. Verfahren zum Gewinnen in einem Molkeprotein mindestens 50% eines Isoflavons von einem Pflanzenproteinmaterial, umfassend:
    (a) Erhalten einer Pflanzenproteinmolke, umfassend Isoflavone,
    (b) Umsetzen der Isoflavone mit einer ausreichenden Menge mindestens eines von beta-Glucosidase und Esterase für eine Zeitdauer, Temperatur und pH, ausreichend, eine Mehrheit der Isoflavone in der Molke zu weniger löslichen Isoflavonen umzuwandeln und dadurch eine Isoflavon angereicherte Molke herzustellen, und
    (c) Gewinnen eines Proteinmaterials aus der Molke unter zur Verfügung stellen eines Molkeproteins, enthaltend mindestens 50% der in dem Pflanzenproteinmaterial enthaltenen Isoflavone.
  29. Verfahren nach Anspruch 28, wobei das Molkeprotein mindestens 65% der in dem Pflanzenproteinmaterial enthaltenen Isoflavone enthält.
  30. Verfahren nach Anspruch 29, wobei das Molkeprotein mindestens 80% der in dem Pflanzenproteinmaterial enthaltenen Isoflavone enthält.
  31. Verfahren nach einem von Ansprüchen 28 bis 30, durchgeführt in Übereinstimmung mit einem von Ansprüchen 1 bis 20.
  32. Aglucon Isoflavon angereichertes Molkeprotein, hergestellt durch das Verfahren nach einem von Ansprüchen 28 bis 31.
  33. Aglucon Isoflavon angereicherte Molke, hergestellt aus einem Verfahren nach einem vorhergehenden Anspruch.
  34. Aglucon Isoflavon angereichertes Pflanzenmolkeprotein mit einem Trockenbasisgenisteingehalt von 2,6 bis 8,7 mg/g und einem Trockenbasisdaidzeingehalt von 2,5 bis 6,0 mg/g.
EP94928641A 1993-10-12 1994-09-21 Ein aglucon isoflavon angereichertes pflanzliches molkeprotein, und ein verfahren zur herstellung Expired - Lifetime EP0723536B2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13519293A 1993-10-12 1993-10-12
US135192 1993-10-12
PCT/US1994/010699 WO1995010512A1 (en) 1993-10-12 1994-09-21 An aglucone isoflavone enriched vegetable protein whey, whey protein, and process for producing

Publications (4)

Publication Number Publication Date
EP0723536A1 EP0723536A1 (de) 1996-07-31
EP0723536A4 EP0723536A4 (de) 1998-09-23
EP0723536B1 true EP0723536B1 (de) 2002-04-03
EP0723536B2 EP0723536B2 (de) 2006-06-14

Family

ID=22466955

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94928641A Expired - Lifetime EP0723536B2 (de) 1993-10-12 1994-09-21 Ein aglucon isoflavon angereichertes pflanzliches molkeprotein, und ein verfahren zur herstellung

Country Status (11)

Country Link
US (1) US5637561A (de)
EP (1) EP0723536B2 (de)
JP (3) JP3787844B2 (de)
KR (1) KR100303909B1 (de)
CN (1) CN1065864C (de)
AU (1) AU680554B2 (de)
BR (3) BR9407822A (de)
CA (1) CA2173999C (de)
DE (1) DE69430314T3 (de)
RU (1) RU2130073C1 (de)
WO (1) WO1995010512A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830887A (en) 1992-05-19 1998-11-03 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
EP0804462B2 (de) * 1993-10-12 2006-06-14 Archer Daniels Midland Company Aglucon-isoflavon-angereicherter pflanzicher protein, isolat und herstellungsprozess
US5827682A (en) * 1995-06-07 1998-10-27 Protein Technologies International, Inc. Two-step conversion of vegetable protein isoflavone conjugates to aglucones
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
US6391310B1 (en) 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of neurological symptoms
US6261565B1 (en) 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US5851792A (en) * 1996-04-03 1998-12-22 Shen; Jerome Aglucone isoflavone enriched vegetable protein whey whey protein material aglucone isoflavone material high genistein content material and high daidzein content material and process for producing the same from a vegetable protein whey
US6015785A (en) * 1996-04-12 2000-01-18 Protein Technologies International, Inc. Aglucone isofavone enriched vegetable protein extract and isolate and process for producing
US5821361A (en) * 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US6579561B2 (en) 1996-08-09 2003-06-17 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable flour and vegetable grit and process for making the same from a vegetable material containing isoflavone
US6521282B1 (en) 1996-08-09 2003-02-18 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable flour and grit
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5726034A (en) * 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
PL332306A1 (en) * 1996-09-20 1999-08-30 Howard Foundation Method of obtaining composition containing polyphenoles
US6569446B1 (en) 1996-09-20 2003-05-27 The Howard Foundation Solubilization of flavonols
US6238673B1 (en) 1996-09-20 2001-05-29 The Howard Foundation Method of producing high flavonol content polyphenol compositions
AUPO644897A0 (en) * 1997-04-28 1997-05-22 Novogen Inc Preparation of isoflavones from legumes
US6146668A (en) * 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
US6340703B1 (en) * 1997-05-01 2002-01-22 Novogen, Inc. Treatment or prevention of osteoporosis
US5834605A (en) * 1997-07-07 1998-11-10 Liu; Yaguang Safe pharmaceutical composition for treating and preventing alcohol abuse and increasing immune function
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
CN1114351C (zh) * 1997-10-17 2003-07-16 蛋白质技术国际公司 富含配基异黄酮的植物蛋白乳清及其生产方法
KR100413025B1 (ko) * 1997-10-20 2004-04-29 솔레 엘엘씨 아글루콘이소플라본강화식물성단백질유장,유장단백질재료,아글루콘이소플라본재료,제니스테인함량이높은재료및디아드제인함량이높은재료및식물성단백질유장으로부터이들을제조하는방법
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
AUPP260798A0 (en) 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
US5994508A (en) * 1998-04-13 1999-11-30 Protein Technologies International, Inc. Isoflavone rich protein isolate and process for producing
US6083553A (en) * 1998-06-05 2000-07-04 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US6013771A (en) * 1998-06-09 2000-01-11 Protein Technologies International, Inc. Isoflavone rich protein isolate and process for producing
US6150399A (en) * 1998-06-30 2000-11-21 Abbott Laboratories Soy-based nutritional products
CA2344458A1 (en) 1998-09-30 2000-04-06 Amano Enzyme Inc. Novel enzyme composition and production method and use thereof
US6703051B1 (en) 1998-10-13 2004-03-09 Solae, Llc Process for separating and recovering protein and isoflavones from a plant material
JP2002530347A (ja) 1998-11-25 2002-09-17 ニュートリ・ファーマ・アルメント・アクシェセルスカブ 大豆蛋白質、食物繊維およびフィトエストロゲン化合物を含む組成物、および心臓血管疾患の予防および／または治療におけるその使用
ATE242638T1 (de) 1998-11-25 2003-06-15 Nutri Pharma As Verwendung einer zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen zur vorbeugung und/oder behandlung von lungenerkrankungen
IL143173A0 (en) 1998-12-02 2002-04-21 Cognis Corp A process for the recovery of isoflavone values from natural sources
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
US7285297B1 (en) 1999-04-23 2007-10-23 Archer-Daniels-Midland Company Method of reducing low density liproprotein cholesterol concentration
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US7182972B2 (en) * 1999-12-17 2007-02-27 Quercegen Pharma, Llc Water-soluble bean-based extracts
CN100366184C (zh) 1999-12-17 2008-02-06 小野光则 水溶性豆类萃取物
US6541062B2 (en) 1999-12-17 2003-04-01 Mitsunori Ono Water-soluble soybean extracts
NZ519931A (en) * 2000-01-11 2003-01-31 Biorex Health Ltd Production of an enriched flavonoid aglycone extract from plant material using enzymes
AUPQ504300A0 (en) 2000-01-11 2000-02-03 Biorex Health Limited Extraction of flavonoids
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
JP2001204486A (ja) * 2000-01-28 2001-07-31 Kikkoman Corp イソフラボンアグリコン含有組成物の製造方法
RU2002125861A (ru) * 2000-03-29 2004-02-20 Амано Энзайм Инк. (Jp) Способ получения агликона с использованием дигликозидазы и продукта питания с улучшенным вкусом, содержащего агликон, и используемый в способе превращающий агент
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US6811804B2 (en) * 2001-06-07 2004-11-02 Abbott Laboratories Juice and soy protein beverage and uses thereof
AUPR602201A0 (en) * 2001-06-29 2001-07-26 Biorex Health Limited Flavonoid concentrates
US20040071685A1 (en) * 2002-10-09 2004-04-15 Devin Houston Compositions and methods for increasing the bioavailability of plant polyphenols
BRPI0510967A (pt) 2004-05-10 2007-11-20 Itesm inibição do crescimento de células cancerìgenas por extratos de feijão preto (phaseolus vulgaris l)
WO2007011870A2 (en) * 2005-07-15 2007-01-25 Amano Enzyme Usa Co., Ltd Enzyme compositions that enhance the flavor of food and beverages
EP2195030B1 (de) * 2007-09-14 2014-05-07 CamNutra Limited Isoflavon-formulierung
GB0723102D0 (en) * 2007-11-26 2008-01-02 Univ Brighton Bioactive and resorbable soy-based biomaterials
US20090176871A1 (en) * 2008-01-07 2009-07-09 Schoenwetter Phillip E Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones
US8426189B2 (en) * 2009-04-29 2013-04-23 Fermalogic, Inc. Soybean-based fermentation media, methods of making and use
FR2974300B1 (fr) 2011-04-19 2013-05-10 Inneov Lab Utilisation d'une combinaison d'un carotenoide, d'un phytoestrogene et de la vitamine c pour la prevention et/ou le traitement de desordres pigmentaires
FR2974296B1 (fr) 2011-04-19 2013-05-24 Inneov Lab Utilisation d'une combinaison d'un carotenoide, d'un phytoestrogene et de la vitamine c en tant qu'actif pour l'hydratation de la peau
FR2996135A1 (fr) 2012-09-28 2014-04-04 Inneov Lab Composition orale pour renforcer la tolerance cutanee suite a une administration topique d'un compose retinoide.
CN112410321B (zh) * 2020-11-26 2022-01-28 昆明理工大学 一种β-葡萄糖苷酶Ttbgl3及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE616786A (fr) * 1961-04-26 1962-08-16 Spofa Vereinigte Pharma Werke Procédé de préparation d'une substance efficace contre les inflammations
US3391001A (en) * 1965-02-26 1968-07-02 Griffith Laboratories Production of flavorful protein hydrolysate
US3870805A (en) * 1970-11-04 1975-03-11 Staley Mfg Co A E Process for preparing texturized protein compositions and the resulting product
US3780182A (en) * 1971-01-18 1973-12-18 Kraftco Corp Method for imparting cheese-like flavor to proteinaceous materials
GB1446965A (en) * 1974-02-14 1976-08-18 Agricultural Vegetable Prod Preparation of food products
JPS5129280A (en) * 1974-08-12 1976-03-12 Kikkoman Shoyu Co Ltd Daizuno kakoshorihoho
US4889921A (en) * 1987-04-29 1989-12-26 The University Of Toronto Innovations Foundation Production of rapeseed protein materials
JPH0714927B2 (ja) * 1988-04-06 1995-02-22 キッコーマン株式会社 イソフラボン化合物の製造法
EP0804462B2 (de) * 1993-10-12 2006-06-14 Archer Daniels Midland Company Aglucon-isoflavon-angereicherter pflanzicher protein, isolat und herstellungsprozess
US5320949A (en) * 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
RU2151775C1 (ru) * 1993-10-12 2000-06-27 Протеин Текнолоджиз Интернэшнл, Инк. Способ получения концентрата белка, способ извлечения изофлавона в концентрат белка, концентрат белка (варианты)

Also Published As

Publication number Publication date
CN1065864C (zh) 2001-05-16
EP0723536B2 (de) 2006-06-14
DE69430314D1 (de) 2002-05-08
AU680554B2 (en) 1997-07-31
JP2007119491A (ja) 2007-05-17
BR1101092A (pt) 2000-03-14
CA2173999C (en) 2008-09-09
EP0723536A1 (de) 1996-07-31
DE69430314T2 (de) 2002-11-14
JPH09506077A (ja) 1997-06-17
CA2173999A1 (en) 1995-04-20
CN1135214A (zh) 1996-11-06
DE69430314T3 (de) 2006-11-23
RU2130073C1 (ru) 1999-05-10
BR9407822A (pt) 1997-05-06
US5637561A (en) 1997-06-10
WO1995010512A1 (en) 1995-04-20
EP0723536A4 (de) 1998-09-23
JP2006087440A (ja) 2006-04-06
BR1101108A (pt) 2000-03-14
JP3787844B2 (ja) 2006-06-21
KR100303909B1 (ko) 2001-11-30
AU7800294A (en) 1995-05-04

Similar Documents

Publication Publication Date Title
EP0723536B1 (de) Ein aglucon isoflavon angereichertes pflanzliches molkeprotein, das molkeprotein und ein verfahren zur herstellung
EP0804462B1 (de) Aglucon-isoflavon-angereicherter pflanzicher proteinextrakt, isolat und herstellungsprozess
EP0794960B2 (de) Ein aglukon isoflavon angereichertes pflanzenproteinkonzentrat und ein verfahren zu dessen herstellung
EP0812837B1 (de) Gewinnung von Isoflavonen aus Sojamelasse
KR100411647B1 (ko) 식물성단백질이소플라본결합체의아글루콘으로의2단계전환방법
US6015785A (en) Aglucone isofavone enriched vegetable protein extract and isolate and process for producing
AU738774B2 (en) An aglucone isoflavone enriched vegetable protein extract and isolate and process for producing
MXPA98003598A (en) An extract and isolated vegetable protein enriched with aglucone isoflavone, and procedure to produce

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE FR GB IT NL

A4 Supplementary search report drawn up and despatched

Effective date: 19980803

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE DE FR GB IT NL

17Q First examination report despatched

Effective date: 19991206

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE DE FR GB IT NL

REF Corresponds to:

Ref document number: 69430314

Country of ref document: DE

Date of ref document: 20020508

ET Fr: translation filed
PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

26 Opposition filed

Opponent name: ARCHER-DANIELS-MIDLAND CORPORATION

Effective date: 20021227

NLR1 Nl: opposition has been filed with the epo

Opponent name: ARCHER-DANIELS-MIDLAND CORPORATION

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: SOLAE, LLC

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: SOLAE, LLC

PLAQ Examination of admissibility of opposition: information related to despatch of communication + time limit deleted

Free format text: ORIGINAL CODE: EPIDOSDOPE2

PLAR Examination of admissibility of opposition: information related to receipt of reply deleted

Free format text: ORIGINAL CODE: EPIDOSDOPE4

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

RTI2 Title (correction)

Free format text: AN AGLUCONE ISOFLAVONE ENRICHED VEGETABLE PROTEIN WHEY, AND PROCESS FOR PRODUCING

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ARCHER DANIELS MIDLAND COMPANY

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20060614

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): BE DE FR GB IT NL

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: ARCHER DANIELS MIDLAND COMPANY

Effective date: 20060426

NLR2 Nl: decision of opposition

Effective date: 20060614

NLR3 Nl: receipt of modified translations in the netherlands language after an opposition procedure
ET3 Fr: translation filed ** decision concerning opposition
NLS Nl: assignments of ep-patents

Owner name: ARCHER DANIELS MIDLAND COMPANY

Effective date: 20070904

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070926

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CD

Ref country code: FR

Ref legal event code: CA

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20070923

Year of fee payment: 14

Ref country code: IT

Payment date: 20070927

Year of fee payment: 14

Ref country code: DE

Payment date: 20071031

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20071025

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070917

Year of fee payment: 14

BERE Be: lapsed

Owner name: *ARCHER DANIELS MIDLAND CY

Effective date: 20080930

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090401

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20090401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20090529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080921

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080921